Massachusetts General Hospital: Leukemia, Myeloid, Acute trials
The registry lists 28 Leukemia, Myeloid, Acute studies with Massachusetts General Hospital as lead sponsor. 5 are open to participants now and 2 have results posted.
Phase 1 14Phase 2 6No phase 8(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AMLRecruitingNCT07355335Phase 1
- Ivosidenib as Post-HSCT Maintenance for AMLRecruitingNCT06707493Phase 2
- Novel Digital Application for Patients With Acute LeukemiaRecruitingNCT06472128Not applicable
- Ziftomenib Maintenance Post Allo-HCTRecruitingNCT06440135Phase 1
- Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid LeukemiaRecruitingNCT05237258Not applicable
- Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AMLCompletedNCT02560025Phase 2Results posted
- Reduced Intensity Double Umbilical Cord Blood TransplantationCompletedNCT01408563Phase 2Results posted
- Psychological Mobile App for Patients With AMLTerminatedNCT05501171Not applicable
- Acquired Pyruvate Kinase Deficiency In Clonal Myeloid NeoplasmsCompletedNCT04902833
- Venetoclax + Azacitidine vs. Induction Chemotherapy in AMLActive, not recruitingNCT04801797Phase 2
- IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell TransplantationCompletedNCT03515512Phase 1
- Psychological Intervention Mobile App for Patients With AMLCompletedNCT03372291Not applicable
- A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive TherapyActive, not recruitingNCT03310918Not applicable
- Ruxolitinib + Allogeneic Stem Cell Transplantation in AMLActive, not recruitingNCT03286530Phase 2
- Study of Regorafenib in Patients With Advanced Myeloid MalignanciesCompletedNCT03042689Phase 1
- A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid LeukemiaCompletedNCT02975869Not applicable
- Volasertib Combined With Induction Chemotherapy in Acute Myeloid LeukemiaWithdrawnNCT02905994Phase 1
- MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of AgeCompletedNCT02582359Phase 1
- Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell TransplantationCompletedNCT02312102Phase 1
- Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AMLTerminatedNCT02255162Phase 1
- Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01961765Phase 1
- Sulindac for Patients With AMLWithdrawnNCT01843179Phase 2
- Brentuximab Vedotin + Re-induction Chemotherapy for AMLCompletedNCT01830777Phase 1
- Alisertib for Acute Myeloid LeukemiaCompletedNCT01779843Phase 1
- Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood DisordersCompletedNCT01758042Not applicable
- Lenalidomide Plus Chemotherapy for AMLCompletedNCT01681537Phase 1
- VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous LeukemiaCompletedNCT00505700Phase 1
- Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization.CompletedNCT00299780Phase 1